BP p.l.c. (RNS)

  • ISIN: GB0007980591
  • Land: UK

Alle Mitteilungen

DGAP-News 29.11.21 19:12 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 26.11.21 19:25 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 26.11.21 15:00 DGAP-News: BP p.l.c. (RNS)
BP p.l.c. publishes provisional dividend dates
DGAP-News 25.11.21 19:31 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 24.11.21 19:45 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 23.11.21 19:21 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 22.11.21 18:55 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 19.11.21 19:00 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 18.11.21 19:00 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 17.11.21 19:50 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 16.11.21 19:56 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 15.11.21 19:41 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 12.11.21 20:30 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 11.11.21 20:00 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 11.11.21 19:20 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Director/PDMR Shareholding
DGAP-News 10.11.21 20:00 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 09.11.21 20:15 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 09.11.21 06:30 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 08.11.21 20:29 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares
DGAP-News 05.11.21 20:01 DGAP-News: BP p.l.c. (RNS)
BP p.l.c.: Transaction in Own Shares

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021